BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Scharl M, Seibold F, Straumann A, Michetti P. Efficacy and safety of certolizumab pegol in an unselected crohnʼs disease population: 26-week data of the FACTS II survey. Inflammatory Bowel Diseases 2011;17:1530-9. [DOI: 10.1002/ibd.21521] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Ferrante M, Vermeire S, Rutgeerts P. Certolizumab pegol in the treatment of Crohn's disease. Expert Opinion on Biological Therapy 2013;13:595-605. [DOI: 10.1517/14712598.2013.777039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
2 Evans AT, Lee SD. A review and expert opinion of the use of certolizumab for Crohn's disease. Expert Opin Biol Ther 2012;12:363-70. [PMID: 22339409 DOI: 10.1517/14712598.2012.658770] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
3 Gilet H, Arnould B, Fofana F, Clerson P, Colombel JF, D'Hondt O, Faure P, Hagège H, Nachury M, Nahon S, Tucat G, Vandromme L, Cazala-Telinge I, Thibout E. Measuring patients' satisfaction with their anti-TNF treatment in severe Crohn's disease: scoring and psychometric validation of the Satisfaction for PAtients in Crohn's diseasE Questionnaire (SPACE-Q(©)). Patient Prefer Adherence 2014;8:1671-81. [PMID: 25525343 DOI: 10.2147/PPA.S72004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Ivens IA, Baumann A, Mcdonald TA, Humphries TJ, Michaels LA, Mathew P. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia 2013;19:11-20. [DOI: 10.1111/j.1365-2516.2012.02931.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 7.3] [Reference Citation Analysis]
5 Blonski W, Buchner AM, Lichtenstein GR. Patient adherence and efficacy of certolizumab pegol in the management of Crohn's disease. Clin Med Insights Gastroenterol 2012;5:11-21. [PMID: 24833930 DOI: 10.4137/CGast.S7613] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
6 Capogrosso Sansone A, Mantarro S, Tuccori M, Ruggiero E, Montagnani S, Convertino I, Marino A, Fornai M, Antonioli L, Corona T, Garibaldi D, Blandizzi C. Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. Drug Saf 2015;38:869-88. [DOI: 10.1007/s40264-015-0336-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
7 Augustine JM, Lee JK, Armstrong EP. Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease. Expert Rev Pharmacoecon Outcomes Res 2014;14:599-609. [PMID: 25209304 DOI: 10.1586/14737167.2014.957680] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Girardin M, Manz M, Manser C, Biedermann L, Wanner R, Frei P, Safroneeva E, Mottet C, Rogler G, Schoepfer AM. First-line therapies in inflammatory bowel disease. Digestion. 2012;86 Suppl 1:6-10. [PMID: 23051720 DOI: 10.1159/000341951] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
9 Cohen LB, Nanau RM, Delzor F, Neuman MG. Biologic therapies in inflammatory bowel disease. Translational Research 2014;163:533-56. [DOI: 10.1016/j.trsl.2014.01.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
10 Coe CL, Horst SN, Izzy MJ. Neurologic Toxicities Associated with Tumor Necrosis Factor Inhibitors and Calcineurin Inhibitors. Neurol Clin 2020;38:937-51. [PMID: 33040870 DOI: 10.1016/j.ncl.2020.07.009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Renna S, Orlando A, Cottone M. Comparing medical treatments for Crohn's disease. J Comp Eff Res 2013;2:135-49. [PMID: 24236556 DOI: 10.2217/cer.13.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Moon W, Pestana L, Becker B, Loftus EV, Hanson KA, Bruining DH, Tremaine WJ, Kane SV. Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice. Aliment Pharmacol Ther. 2015;42:428-440. [PMID: 26081839 DOI: 10.1111/apt.13288] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
13 Schoepfer AM, Safroneeva E, Vavricka SR, Peyrin-Biroulet L, Mottet C. Treatment of fibrostenotic and fistulizing Crohn’s disease. Digestion. 2012;86 Suppl 1:23-27. [PMID: 23051723 DOI: 10.1159/000341961] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
14 Brandse JF, Peters CP, Gecse KB, Eshuis EJ, Jansen JM, Tuynman HA, Löwenberg M, Ponsioen CY, van den Brink GR, Dʼhaens GR. Effects of Infliximab Retreatment After Consecutive Discontinuation of Infliximab and Adalimumab in Refractory Crohnʼs Disease: . Inflammatory Bowel Diseases 2014;20:251-8. [DOI: 10.1097/01.mib.0000438248.14218.1d] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
15 Ferrante M, Vermeire S, Rutgeerts PJ. Drug safety evaluation of certolizumab pegol. Expert Opin Drug Saf 2014;13:255-66. [PMID: 24156537 DOI: 10.1517/14740338.2014.851666] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]